Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies

Yoon Kong Loke, Chun Shing Kwok, Sonal Singh

Research output: Contribution to journalArticle

Abstract

Objective: To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes. Design: Systematic review and meta-analysis of observational studies. Data sources: Searches of Medline and Embase in September 2010. Study selection: Observational studies that directly compared the risk of cardiovascular outcomes for rosiglitazone and pioglitazone among patients with type 2 diabetes mellitus were included. Data extraction: Random effects meta-analysis (inverse variance method) was used to calculate the odds ratios for cardiovascular outcomes with thiazolidinedione use. The I2 statistic was used to assess statistical heterogeneity. Results: Cardiovascular outcomes from 16 observational studies (4 case-control studies and 12 retrospective cohort studies), including 810 000 thiazolidinedione users, were evaluated after a detailed review of 189 citations. Compared with pioglitazone, use of rosiglitazone was associated with a statistically significant increase in the odds of myocardial infarction (n=15 studies; odds ratio 1.16, 95% confidence interval 1.07 to 1.24; P2=46%), congestive heart failure (n=8; 1.22, 1.14 to 1.31; P2=37%), and death (n=8; 1.14, 1.09 to 1.20; P2=0%). Numbers needed to treat to harm (NNH), depending on the population at risk, suggest 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone. Conclusion: Among patients with type 2 diabetes, use of rosiglitazone is associated with significantly higher odds of congestive heart failure, myocardial infarction, and death relative to pioglitazone in real world settings.

Original languageEnglish (US)
Article numberd1309
Pages (from-to)692
Number of pages1
JournalBMJ (Online)
Volume342
Issue number7799
DOIs
StatePublished - Mar 26 2011

Fingerprint

rosiglitazone
pioglitazone
Thiazolidinediones
Observational Studies
Meta-Analysis
Heart Failure
Myocardial Infarction
Type 2 Diabetes Mellitus
Odds Ratio
Numbers Needed To Treat
Information Storage and Retrieval
Case-Control Studies
Analysis of Variance
Cohort Studies
Retrospective Studies
Confidence Intervals
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Comparative cardiovascular effects of thiazolidinediones : Systematic review and meta-analysis of observational studies. / Loke, Yoon Kong; Kwok, Chun Shing; Singh, Sonal.

In: BMJ (Online), Vol. 342, No. 7799, d1309, 26.03.2011, p. 692.

Research output: Contribution to journalArticle

Loke, Yoon Kong ; Kwok, Chun Shing ; Singh, Sonal. / Comparative cardiovascular effects of thiazolidinediones : Systematic review and meta-analysis of observational studies. In: BMJ (Online). 2011 ; Vol. 342, No. 7799. pp. 692.
@article{3785dc467ce9417cb9f7bfb449c93d37,
title = "Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies",
abstract = "Objective: To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes. Design: Systematic review and meta-analysis of observational studies. Data sources: Searches of Medline and Embase in September 2010. Study selection: Observational studies that directly compared the risk of cardiovascular outcomes for rosiglitazone and pioglitazone among patients with type 2 diabetes mellitus were included. Data extraction: Random effects meta-analysis (inverse variance method) was used to calculate the odds ratios for cardiovascular outcomes with thiazolidinedione use. The I2 statistic was used to assess statistical heterogeneity. Results: Cardiovascular outcomes from 16 observational studies (4 case-control studies and 12 retrospective cohort studies), including 810 000 thiazolidinedione users, were evaluated after a detailed review of 189 citations. Compared with pioglitazone, use of rosiglitazone was associated with a statistically significant increase in the odds of myocardial infarction (n=15 studies; odds ratio 1.16, 95{\%} confidence interval 1.07 to 1.24; P2=46{\%}), congestive heart failure (n=8; 1.22, 1.14 to 1.31; P2=37{\%}), and death (n=8; 1.14, 1.09 to 1.20; P2=0{\%}). Numbers needed to treat to harm (NNH), depending on the population at risk, suggest 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone. Conclusion: Among patients with type 2 diabetes, use of rosiglitazone is associated with significantly higher odds of congestive heart failure, myocardial infarction, and death relative to pioglitazone in real world settings.",
author = "Loke, {Yoon Kong} and Kwok, {Chun Shing} and Sonal Singh",
year = "2011",
month = "3",
day = "26",
doi = "10.1136/bmj.d1309",
language = "English (US)",
volume = "342",
pages = "692",
journal = "British Medical Journal",
issn = "0959-8146",
publisher = "BMJ Publishing Group",
number = "7799",

}

TY - JOUR

T1 - Comparative cardiovascular effects of thiazolidinediones

T2 - Systematic review and meta-analysis of observational studies

AU - Loke, Yoon Kong

AU - Kwok, Chun Shing

AU - Singh, Sonal

PY - 2011/3/26

Y1 - 2011/3/26

N2 - Objective: To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes. Design: Systematic review and meta-analysis of observational studies. Data sources: Searches of Medline and Embase in September 2010. Study selection: Observational studies that directly compared the risk of cardiovascular outcomes for rosiglitazone and pioglitazone among patients with type 2 diabetes mellitus were included. Data extraction: Random effects meta-analysis (inverse variance method) was used to calculate the odds ratios for cardiovascular outcomes with thiazolidinedione use. The I2 statistic was used to assess statistical heterogeneity. Results: Cardiovascular outcomes from 16 observational studies (4 case-control studies and 12 retrospective cohort studies), including 810 000 thiazolidinedione users, were evaluated after a detailed review of 189 citations. Compared with pioglitazone, use of rosiglitazone was associated with a statistically significant increase in the odds of myocardial infarction (n=15 studies; odds ratio 1.16, 95% confidence interval 1.07 to 1.24; P2=46%), congestive heart failure (n=8; 1.22, 1.14 to 1.31; P2=37%), and death (n=8; 1.14, 1.09 to 1.20; P2=0%). Numbers needed to treat to harm (NNH), depending on the population at risk, suggest 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone. Conclusion: Among patients with type 2 diabetes, use of rosiglitazone is associated with significantly higher odds of congestive heart failure, myocardial infarction, and death relative to pioglitazone in real world settings.

AB - Objective: To determine the comparative effects of the thiazolidinediones (rosiglitazone and pioglitazone) on myocardial infarction, congestive heart failure, and mortality in patients with type 2 diabetes. Design: Systematic review and meta-analysis of observational studies. Data sources: Searches of Medline and Embase in September 2010. Study selection: Observational studies that directly compared the risk of cardiovascular outcomes for rosiglitazone and pioglitazone among patients with type 2 diabetes mellitus were included. Data extraction: Random effects meta-analysis (inverse variance method) was used to calculate the odds ratios for cardiovascular outcomes with thiazolidinedione use. The I2 statistic was used to assess statistical heterogeneity. Results: Cardiovascular outcomes from 16 observational studies (4 case-control studies and 12 retrospective cohort studies), including 810 000 thiazolidinedione users, were evaluated after a detailed review of 189 citations. Compared with pioglitazone, use of rosiglitazone was associated with a statistically significant increase in the odds of myocardial infarction (n=15 studies; odds ratio 1.16, 95% confidence interval 1.07 to 1.24; P2=46%), congestive heart failure (n=8; 1.22, 1.14 to 1.31; P2=37%), and death (n=8; 1.14, 1.09 to 1.20; P2=0%). Numbers needed to treat to harm (NNH), depending on the population at risk, suggest 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone. Conclusion: Among patients with type 2 diabetes, use of rosiglitazone is associated with significantly higher odds of congestive heart failure, myocardial infarction, and death relative to pioglitazone in real world settings.

UR - http://www.scopus.com/inward/record.url?scp=79953203593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953203593&partnerID=8YFLogxK

U2 - 10.1136/bmj.d1309

DO - 10.1136/bmj.d1309

M3 - Article

C2 - 21415101

AN - SCOPUS:79953203593

VL - 342

SP - 692

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8146

IS - 7799

M1 - d1309

ER -